Mirko Scarsi1, Tamara Ziglioli, Paolo Airò. 1. Rheumatology and Clinical Immunology Service, Spedali Civili and University of Brescia, Brescia, Italy.
Abstract
OBJECTIVE: To verify the hypothesis that blockade of CD28 costimulation by treatment with abatacept in patients with rheumatoid arthritis (RA) might induce a reduction in the number of CD28- T cells, as well as other effector T cell populations. We evaluated whether these variations correlate with clinical response. METHODS: Peripheral blood T cell subsets were longitudinally evaluated by flow cytometry through the analysis of CD28, CD45RA, and CCR7 expression in 16 patients with RA who were treated with abatacept. RESULTS: After 48 weeks of treatment, the proportion and the absolute number of circulating CD8+CD28- T cells decreased (p = 0.008, p = 0.055, respectively, compared with baseline), as well as the proportion of the CD8+CD45RA+CCR7- cells, thought to represent terminally differentiated effector T cells (p = 0.03). Reductions of percentages of circulating CD4+CD28- and CD8+CD28- T cells, and (CCR7-) CD8+ total effector T cells were directly correlated with the reduction of Disease Activity Score 28 C-reactive protein (r = 0.58, p = 0.014; r = 0.47, p = 0.059; r = 0.59, p = 0.012, respectively). CONCLUSION: After therapy with abatacept, circulating CD28- T cells and other effector populations decrease in patients with RA. This decrease is correlated with clinical response.
OBJECTIVE: To verify the hypothesis that blockade of CD28 costimulation by treatment with abatacept in patients with rheumatoid arthritis (RA) might induce a reduction in the number of CD28- T cells, as well as other effector T cell populations. We evaluated whether these variations correlate with clinical response. METHODS: Peripheral blood T cell subsets were longitudinally evaluated by flow cytometry through the analysis of CD28, CD45RA, and CCR7 expression in 16 patients with RA who were treated with abatacept. RESULTS: After 48 weeks of treatment, the proportion and the absolute number of circulating CD8+CD28- T cells decreased (p = 0.008, p = 0.055, respectively, compared with baseline), as well as the proportion of the CD8+CD45RA+CCR7- cells, thought to represent terminally differentiated effector T cells (p = 0.03). Reductions of percentages of circulating CD4+CD28- and CD8+CD28- T cells, and (CCR7-) CD8+ total effector T cells were directly correlated with the reduction of Disease Activity Score 28 C-reactive protein (r = 0.58, p = 0.014; r = 0.47, p = 0.059; r = 0.59, p = 0.012, respectively). CONCLUSION: After therapy with abatacept, circulating CD28- T cells and other effector populations decrease in patients with RA. This decrease is correlated with clinical response.
Authors: Joerg Ermann; Deepak A Rao; Nikola C Teslovich; Michael B Brenner; Soumya Raychaudhuri Journal: Nat Rev Rheumatol Date: 2015-06-02 Impact factor: 20.543
Authors: Amit D Parulekar; Jonathan S Boomer; Brenda M Patterson; Huiqing Yin-Declue; Christine M Deppong; Brad S Wilson; Nizar N Jarjour; Mario Castro; Jonathan M Green Journal: Am J Respir Crit Care Med Date: 2013-01-04 Impact factor: 21.405
Authors: Chamith Y Fonseka; Deepak A Rao; Nikola C Teslovich; Ilya Korsunsky; Susan K Hannes; Kamil Slowikowski; Michael F Gurish; Laura T Donlin; James A Lederer; Michael E Weinblatt; Elena M Massarotti; Jonathan S Coblyn; Simon M Helfgott; Derrick J Todd; Vivian P Bykerk; Elizabeth W Karlson; Joerg Ermann; Yvonne C Lee; Michael B Brenner; Soumya Raychaudhuri Journal: Sci Transl Med Date: 2018-10-17 Impact factor: 19.319